Contagion, December 2020 (Vol. 05 No. 06)
An expert panel discussion around long-acting injectables' role in both preventing and treating HIV.
Biologics have become a novel treatment in recurrent C. difficile.
Since late 2004, 7 novel antibiotics with activity against ESBL-E, CRE, and/or DTR P aeruginosa have been approved.
Fostemsavir, an HIV-1 attachment inhibitor, is a novel therapeutic option for multidrug-resistant HIV. It represents the first oral agent developed for this indication in over a decade and provides promise for patients with limited remaining treatment options.
Advertisement
Advertisement
Trending on Contagion Live
1
Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint
2
Dynavax Presents Data for Shingles Vaccine, Launches Head-to-Head Study Against Shingrix
3
Risk Stratification, Testing, and Treatment in Recurrent Clostridioides difficile
4
Nearly 1 in 5 Urinary Tract Infections in Southern California Linked to Contaminated Meat
5
